Single-Inhaler Triple vs Long-Acting Beta₂-Agonist-Inhaled Corticosteroid Therapy for COPD: Comparative Safety in Real-World Clinical Practice.

ABSTRACT:

Background

Recent treatment guidelines for COPD have replaced the long-acting beta₂-agonist (LABA) and inhaled corticosteroid (ICS) combination with single-inhaler triple therapy that adds a long-acting muscarinic antagonist (LAMA). However, the corresponding trials reported numerically higher incidences of cardiovascular adverse events with triple therapy compared with LABA-ICS.

Research question

Does single-inhaler triple therapy increase the incidence of major adverse cardiovascular events, compared with LABA-ICS, in a real-world clinical practice setting?

Study design and methods

We identified a cohort of patients with COPD aged ≥ 40 years treated during 2017-2021 from the UK's Clinical Practice Research Datalink. Among LAMA-naive patients, initiators o

SUBMITTER: Suissa S 

PROVIDER: S-EPMC11882741 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature